kB-1388

Vunakizumab

Home » Antibody » Vunakizumab

Background

Vunakizumab (also known as SHR-1314) stands as an innovative humanized monoclonal immunoglobulin of the IgG1/? isotype, directed towards targeting IL-17A. In mouse models, vunakizumab demonstrated remarkable efficiency in antagonizing IL-17, showcasing a level of efficacy in improving psoriasis akin to the tumor necrosis factor inhibitor etanercept. Initial insights gleaned from phase I studies, specifically NCT03710681 and NCT03463187, part A, provided encouraging preliminary data. These findings revealed that when administered subcutaneously at doses ranging from 80 to 240 mg every 2 weeks, vunakizumab exhibited a favorable safety profile and was well-tolerated by patients grappling with plaque psoriasis.

Specifications

Catalog Number:
kB-1388
Cell Line Name:
Vunakizumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
IL17A
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. C.W. Lynde et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol (2014). 2. M. Campa et al. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) (2016).
Please enable JavaScript in your browser to complete this form.